Atomera (ATOM) Q4 2019 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2019 earnings summary
6 Nov, 2026Executive summary
2019 focused on MST technology development; 15 customer engagements were in integration, with more MST wafers at customers and a larger phase 3 customer base than ever before.
Three new technical advances targeted analog power, 5G RF and optimization of advanced-node transistors; the patent portfolio exceeded 200 granted and pending patents worldwide.
Financial highlights
Revenue was $533,000 in 2019 vs. $246,000 in 2018; cost of revenue was $253,000 vs. $148,000.
Operating expenses totaled $13.9 million vs. $13.2 million; operating loss was $13.6 million vs. $13.1 million.
Net loss was $13.3 million vs. $12.9 million; net loss per share was $0.84 vs. $1.02.
R&D expense rose 6% to $7.7 million; G&A increased 5% to $5.2 million, while selling and marketing was nearly flat at $954,000.
Outlook and guidance
Available working capital was expected to fund current plans and obligations for at least 12 months from the March 2020 filing date; ongoing operating losses and additional capital needs remained possible.
Planned spending included increased R&D headcount and outsourced fabrication and testing; meaningful revenue timing depended on lengthy customer qualification and licensing cycles.
Semiconductor customer qualification typically takes 18–36 months or longer; commercial royalties depend on successful high-volume integration and manufacturing and distribution licenses.
Latest events from Atomera
- MST advanced through customer evaluation, but commercial adoption and revenue remained unproven.ATOM
Q4 2016 - MST evaluations expanded, but commercialization remained unproven amid losses and cash burn.ATOM
Q4 2017 - Initial licenses marked progress, but commercialization remains gated by qualification and cash burn.ATOM
Q4 2018 - Cash rose to $37.9 million as a paid manufacturing JDA advanced MST toward commercialization.ATOM
Q4 2020 - JDA milestones and foundry evaluation expanded prospects, but commercialization remained unproven amid $15.7M losses.ATOM
Q4 2021 - Customer milestones advanced, but commercial royalties remain unproven amid continued losses.ATOM
Q4 2022 - FY 2023 revenue was $550K as MST reached two customer fabs and advanced toward royalties.ATOM
Q4 2023 - Q3 revenue was $0 as GAA, memory and IQE-led GaN programs advanced.ATOM
Q3 2026 - Q2 2026 saw a $6.3M net loss, $158K revenue, and major MST milestones in RF and memory.ATOM
Q2 2026